Plenary Session Abstracts and Discussant Presentations-Clinical Safety and Efficacy from the RESET-RA study of a Novel Implantable Neuroimmune Modulation Device for the Treatment of Rheumatoid Arthritis

Clinical Safety and Efficacy from the RESET-RA study of a Novel Implantable Neuroimmune Modulation Device for the Treatment of Rheumatoid Arthritis - Robert Mark Richardson, MD, PhD, FAANS

Back to course

Video Transcription

Video Summary

Dr. Mark Richardson presented six-month safety and efficacy data for a neuroimmunomodulation trial targeting rheumatoid arthritis through vagus nerve stimulation, developed by SetPoint. Originating from neurosurgeon Kevin Tracy's work, this therapy offers an alternative to traditional biologics, which pose infection and malignancy risks. The trial demonstrated that short, daily nerve stimulation reduced joint pain and swelling, providing a potential new treatment pathway for the 75% of patients dissatisfied with current therapies. This innovation fosters collaboration between neurosurgeons and rheumatologists and may soon gain FDA approval.

Keywords

neuroimmunomodulation

vagus nerve stimulation

rheumatoid arthritis

alternative therapy

FDA approval